Senores Pharmaceuticals Ltd vs Zydus Lifesciences Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: Jun 15, 2026

Key Highlights

The Latest Trading Price of Senores Pharmaceuticals Ltd is ₹ 1291 as of 12 Jun 15:30 . The P/E Ratio of Senores Pharmaceuticals Ltd changed from 45 on March 2025 to 45 on March 2025 . This represents a CAGR of 0.00% over 1 yearsThe P/E Ratio of Zydus Lifesciences Ltd changed from 21.1 on March 2021 to 19.7 on March 2025 . This represents a CAGR of -1.36% over 5 years The Market Cap of Senores Pharmaceuticals Ltd changed from ₹ 2637 crore on March 2025 to ₹ 2637 crore on March 2025 . This represents a CAGR of 0.00% over 1 yearsThe Market Cap of Zydus Lifesciences Ltd changed from ₹ 45131 crore on March 2021 to ₹ 89122 crore on March 2025 . This represents a CAGR of 14.58% over 5 years The revenue of Senores Pharmaceuticals Ltd for the Mar '26 is ₹ 192.86 crore as compare to the Dec '25 revenue of ₹ 178.34 crore. This represent the growth of 8.14% The revenue of Zydus Lifesciences Ltd for the Mar '26 is ₹ 7721 crore as compare to the Dec '25 revenue of ₹ 6975 crore. This represent the growth of 10.68% The ebitda of Senores Pharmaceuticals Ltd for the Mar '26 is ₹ 65.16 crore as compare to the Dec '25 ebitda of ₹ 57.79 crore. This represent the growth of 12.75% The ebitda of Zydus Lifesciences Ltd for the Mar '26 is ₹ 2291 crore as compare to the Dec '25 ebitda of ₹ 1842 crore. This represent the growth of 24.32% The net profit of Senores Pharmaceuticals Ltd changed from ₹ 10.91 crore to ₹ 36.67 crore over 8 quarters. This represents a CAGR of 83.33% The net profit of Zydus Lifesciences Ltd changed from ₹ 1463 crore to ₹ 1341 crore over 8 quarters. This represents a CAGR of -4.27% The Dividend Payout of Senores Pharmaceuticals Ltd changed from 0 % on March 2021 to 0 % on March 2025 . This represents a CAGR of 0.0% over 5 yearsThe Dividend Payout of Zydus Lifesciences Ltd changed from 24.28 % on March 2021 to 19.16 % on March 2025 . This represents a CAGR of -4.63% over 5 years .

About Senores Pharmaceuticals Ltd

Senores Pharmaceuticals Limited was originally incorporated as 'Senores Pharmaceuticals Private Limited' through a Certificate of Incorporation dated December 26, 2017, issued by the Registrar of Companies, Central Registration Centre.
Thereafter, the name of the Company was changed to 'Senores Pharmaceuticals Limited' upon conversion to a Public Limited Company and a fresh Certificate of Incorporation dated September 4, 2023, was issued by the RoC to the Company. Senores Pharma is a global research driven pharmaceutical company engaged in developing and manufacturing a wide range of pharmaceutical products predominantly for Regulated Markets across various therapeutic areas and dosage forms.
The Regulated Markets business is focused on Regulated Markets of US and Canada.
The Company has adopted a strategy of identifying, developing and commercializing specialty and complex niche products in the mid-market range and received approvals for 19 ANDAs.

About Zydus Lifesciences Ltd

Zydus Lifesciences Limited, initially known as Cadila Healthcare Limited was incorporated in May, 1995, which changed to Zydus Lifesciences Limited on February 24, 2022.
The Company is one of the leading innovation driven pharmaceutical companies in India with presence across the pharmaceutical value chain including innovating (research & development), manufacturing, marketing and selling of finished dosage human formulations (generics, branded generics and specialty formulations, including biosimilars and vaccines), Active Pharmaceutical Ingredients (APIs), animal healthcare products and consumer wellness products.
The Company operate manufacturing facilities at Ahmedabad, Ankleshwar and Vadodara in Gujarat, Ponda in Goa, Raigad in Maharashtra and Solan in Himachal Pradesh. The Company's operation includes pharmaceuticals, which includes human formulations, veterinary formulations and bulk durgs, diagnostics, herbal products, skin care products and OTC products.

FAQs for the comparison of Senores Pharmaceuticals Ltd and Zydus Lifesciences Ltd

Which company has a larger market capitalization, Senores Pharmaceuticals Ltd or Zydus Lifesciences Ltd?

Market cap of Senores Pharmaceuticals Ltd is 5,946 Cr while Market cap of Zydus Lifesciences Ltd is 111,123 Cr

What are the key factors driving the stock performance of Senores Pharmaceuticals Ltd and Zydus Lifesciences Ltd?

The stock performance of Senores Pharmaceuticals Ltd and Zydus Lifesciences Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Senores Pharmaceuticals Ltd and Zydus Lifesciences Ltd?

As of June 15, 2026, the Senores Pharmaceuticals Ltd stock price is INR ₹1291.25. On the other hand, Zydus Lifesciences Ltd stock price is INR ₹1104.35.

How do dividend payouts of Senores Pharmaceuticals Ltd and Zydus Lifesciences Ltd compare?

To compare the dividend payouts of Senores Pharmaceuticals Ltd and Zydus Lifesciences Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.